TENT5A Increases Glioma Malignancy and Promotes its Progression
Jiali Hu,Lei Zeng,Ronghuan Hu,Dan Gong,Mengmeng Liu,Jianwu Ding,Lei zeng
DOI: https://doi.org/10.2174/0115748928280901231206102637
2024-01-09
Recent Patents on Anti-Cancer Drug Discovery
Abstract:Background:: Recent studies reported that terminal nucleotidyltransferase 5A (TENT5A) is highly expressed in glioblastoma and associated with poor prognosis. In this work, we aim to specify the expression level of TENT5A in different grades of glioma and explore its role in glioma progression. Methods:: GEPIA online tools were used to perform the bioinformatic analysis. qRT-PCR, Western blot, and Immunohistochemistry were performed in glioma cells or tissues. Furthermore, CCK8, colony formation, transwell, flow cytometry and scratch assays were performed. Results:: TENT5A was highly expressed in glioma and its level was associated with the pathological grade of glioma. Knockdown of TENT5A suppressed cell proliferation, colony formation ability, cell invasion and migration. Overexpression of TENT5A was lethal to the glioma cells. Conclusion:: Our data showed that the expression of TENT5A is associated with the pathological grade of glioma. Knockdown of TENT5A decreased the ability of proliferation, invasion and migration of glioma cells. High levels of TENT5A in glioma cells are lethal. Therefore, TENT5A could be a new target for glioma treatment.
oncology,pharmacology & pharmacy
What problem does this paper attempt to address?